Related Experiment Video

Updated: Sep 7, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

CircRNAs: novel therapeutic targets in multiple myeloma

Xinyi Zhou1, Juan Du2

  • 1Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, No. 415 Fengyang Road, Huangpu Area, Shanghai, 200003, China.

Molecular Biology Reports
|June 21, 2022
PubMed
Abstract

Insights

Circular RNAs (circRNAs) are emerging biomarkers in multiple myeloma (MM). This review explores their roles in MM progression and potential clinical applications for diagnosis and treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Circular RNAs (circRNAs) are a novel class of non-coding RNA gaining research interest.
  • Multiple myeloma (MM), a hematological malignancy, urgently requires improved diagnostics and therapeutics.
  • circRNAs are implicated in malignant hemopathies, yet their role in MM remains underexplored.

Purpose of the Study:

  • To review the biological properties and functions of circRNAs in MM.
  • To discuss the clinical utility of circRNAs in MM diagnosis, prognosis, and treatment.

Main Methods:

  • Literature review focusing on circRNA research in MM.
  • Analysis of circRNA's involvement in gene regulation and cancer progression.

Main Results:

  • circRNAs participate in gene transcription, translation, and epigenetic modification.
  • circRNAs regulate cancer cell proliferation, invasion, and metastasis in MM.
  • circRNAs can either promote or inhibit MM occurrence and progression.

Conclusions:

  • circRNAs play a significant role in the pathogenesis of multiple myeloma.
  • circRNAs show potential as promising biomarkers for MM diagnosis and prognosis.
  • circRNAs may offer novel therapeutic targets for multiple myeloma treatment.
Keywords:
Clinical utilityMultiple myelomacircRNA

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K